Additionally, in a clinical study, patients with metastatic melanoma treated with a combination of anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody (IpilimumabTM) and anti-vascular endothelial growth factor A (VEGF-A) antibody (BevacizumabTM) displayed elevations in anti-Gal-3 Abs that correlated with favorable clinical outcomes; this suggested an additional anti-tumor effect directed against Gal-3 via ipilimumab–bevacizumab combination therapy [118]. This evidence concerns the gene CTLA4 and metastatic melanoma.